- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | Sight Sciences GAAP EPS of -$0.64 misses by $0.52 | 1 | Seeking Alpha | ||
| 04.11. | Sight Sciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11. | Sight Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10. | Sight Sciences, Inc.: Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026 | 1 | GlobeNewswire (USA) | ||
| 15.10. | Why Is Sight Sciences Stock Gaining Thursday? | 1 | Benzinga.com | ||
| 01.10. | Sight Sciences, Inc.: Sight Sciences to Debut the OMNI Ultra Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| SIGHT SCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.08. | Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy | 1 | RTTNews | ||
| 19.08. | Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease | 504 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 10.08. | Sight Sciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | Sight Sciences outlines 2026 revenue of $88M-$92M while lowering adjusted operating expense outlook to $92M-$94M | 2 | Seeking Alpha | ||
| 06.08. | Sight Sciences GAAP EPS of -$0.08 beats by $0.06, revenue of $23.4M beats by $1.71M | 1 | Seeking Alpha | ||
| 05.08. | Earnings Call: Sight Sciences hebt Ausblick für 2026 an, Aktie fällt trotz Q2-Wachstum | - | Investing.com Deutsch | ||
| 05.08. | Sight Sciences: Aetna erweitert Kostenerstattung für Glaukom-Systeme | 8 | Investing.com Deutsch | ||
| 05.08. | Sight Sciences wins FDA clearance for Omni Surgical System | 2 | MassDevice | ||
| 05.08. | FDA clears Sight Sciences' OMNI Ultra glaucoma device | 1 | Investing.com | ||
| 04.08. | Sight Sciences, Inc.: Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System | 189 | GlobeNewswire (Europe) | MENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies... ► Artikel lesen | |
| 22.07. | Sight Sciences, Inc.: Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.06. | Sight Sciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 04.03. | Sight Sciences, Inc.: Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance | 233 | GlobeNewswire (Europe) | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing... ► Artikel lesen | |
| 13.01. | Sight Sciences, Inc.: Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights | 391 | GlobeNewswire (Europe) | MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,816 | -2,28 % | Teladoc Health, Inc.: Teladoc Health Announces Chief Legal Officer Transition | NEW YORK, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today announced a leadership transition in its legal function. After 11 years with... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,067 | -1,19 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 0,580 | +10,27 % | Cerenome names Ron Andrews as chief business officer | ||
| ATOSSA THERAPEUTICS | 1,930 | +1,05 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax | Total revenue increased 28% for the quarter and 41% for the six months ended September 30, 2026 compared to same periods last yearU.S. revenue increased 93% for the quarter and 113% for the six months... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | -8,02 % | Tandem Diabetes Care names successor as CEO Sheridan retires | ||
| CO-DIAGNOSTICS | 0,281 | -12,07 % | Co-Diagnostics Reports Third Quarter 2026 Financial Results | Two Regulatory Submissions Under Review in India and the U.S. Third Quarter Operating Expenses Down 12% Year Over YearPlatform Capabilities Expanding with ReadyGo Collaboration, India Connectivity and... ► Artikel lesen | |
| QUIDELORTHO | 10,730 | -0,42 % | QuidelOrtho expects over $80M in 2027 annual savings as it narrows 2026 revenue to $2.52B-$2.54B | ||
| VERU | 2,100 | -4,11 % | Veru executive to present obesity drug data at industry conference | ||
| LIFEWARD | 6,050 | +1,85 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,320 | +0,23 % | Clover Health auf der UBS Global Healthcare Conference: Starkes Wachstum trifft auf steigende Ertragskraft | ||
| SENSEONICS | 11,400 | +30,29 % | Senseonics delivers 'breakout quarter' more than doubling Eversense 365 revenue | ||
| TEMPEST THERAPEUTICS | 0,373 | +3,07 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| NANO-X IMAGING | 0,339 | +44,50 % | Nanox.AI signs distribution deal for cardiac imaging in Thailand | ||
| IMUNON | 0,780 | -0,64 % | IMUNON präsentiert translationale Daten aus Phase-2-Studie bei Eierstockkrebs |
SIGHT SCIENCES INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -4,08 % bei einem Aktienkurs von 10,570 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SIGHT SCIENCES INC finden Sie auf Wallstreet Online.